Lung Cancer | Clinical

December 19, 2020

Jun Zhang, MD, PhD, associate professor, University of Kansas Medical Center, reviews the preferred treatment options for extensive-stage small cell lung cancer in a 73-year-old patient during a Targeted Oncology Case Based Peer Perspective event.

December 18, 2020

The FDA has approved osimertinib as an adjuvant therapy for patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, for use following tumor resection.

December 18, 2020

Ticiana Leal, MD, presents a case of a 61-year-old man with small cell lung cancer.

December 09, 2020

Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer, redirecting attention toward advances in biomarker testing methodologies.

December 08, 2020

The emergence of tyrosine kinase inhibitors in early-stage disease is a late practice-changing development, said Roger C. Lilenbaum, MD.

December 04, 2020

Treatment with lurbinectedin and doxorubicin missed the prespecified end point of overall survival in patients with small cell lung cancer who progressed after 1 prior platinum therapy.

December 01, 2020

The FDA has granted a Fast Track designation to the irinotecan liposome injection as a potential treatment option for patients with small cell lung cancer who progressed following a first-line platinum-based regimen, Ipsen announced, in a press release.

November 29, 2020

The results from the phase 3 CASPIAN trial were reviewed and compared with the phase 3 IMpower133 by Jyoti D. Patel, MD, during a Targeted Oncology Case Based Peer Perspectives event.

November 27, 2020

Alexander Spira, MD, PhD, shares an important message with community oncologists regarding the treatment of patients with lung cancer.

November 21, 2020

During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.